trending Market Intelligence /marketintelligence/en/news-insights/trending/1z9lsrzgMz7P05dGGK05Wg2 content esgSubNav
In This List

US FDA approves Cadila's generic version of Shire's Lialda

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


US FDA approves Cadila's generic version of Shire's Lialda

The U.S. Food and Drug Administration granted Cadila Healthcare Ltd. approval to market mesalamine delayed release tablets USP, 1.2 grams.

The drug is the first approved generic version of Shire PLC's Lialda, a treatment for mild to moderate ulcerative colitis, a type of chronic inflammatory bowel disease.

Estimated brand sales for mesalamine delayed-release tablets USP 1.2 g is $1.15 billion, per the IMS Health moving annual total as of April.

The generic will be manufactured at Cadila's Moraiya facility in Ahmedabad, India.

In May, the U.S. Court of Appeals for the Federal Circuit ruled that Zydus Pharmaceuticals (USA) Inc.'s generic version of Lialda does not infringe on Shire's patent.